Found 10 results
Author Title Type [ Year
Filters: Author is Gordon, Ingelise J [Clear All Filters]
“Chimpanzee Adenovirus Vector Ebola Vaccine.”. N Engl J Med 376 (10). N Engl J Med: 928-938. doi:10.1056/NEJMoa1410863.
. 2017. “Phase 1 Study Of Pandemic H1 Dna Vaccine In Healthy Adults.”. Plos One 10 (4). Plos One: e0123969. doi:10.1371/journal.pone.0123969.
. 2015. “Phase I Randomized Clinical Trial Of Vrc Dna And Rad5 Hiv-1 Vaccine Delivery By Intramuscular (I.m.), Subcutaneous (S.c.) And Intradermal (I.d.) Administration (Vrc 011).”. Plos One 9 (3). Plos One: e91366. doi:10.1371/journal.pone.0091366.
. 2014. “Dna Vaccine Delivered By A Needle-Free Injection Device Improves Potency Of Priming For Antibody And Cd8+ T-Cell Responses After Rad5 Boost In A Randomized Clinical Trial.”. Plos One 8 (4). Plos One: e59340. doi:10.1371/journal.pone.0059340.
. 2013. “Protection Against Malaria By Intravenous Immunization With A Nonreplicating Sporozoite Vaccine.”. Science 341 (6152). Science: 1359-65. doi:10.1126/science.1241800.
. 2013. “Therapeutic Vaccination Expands And Improves The Function Of The Hiv-Specific Memory T-Cell Repertoire.”. J Infect Dis 207 (12). J Infect Dis: 1829-40. doi:10.1093/infdis/jit098.
. 2013. “Dna Priming And Influenza Vaccine Immunogenicity: Two Phase 1 Open Label Randomised Clinical Trials.”. Lancet Infect Dis 11 (12). Lancet Infect Dis: 916-24. doi:10.1016/S1473-3099(11)70240-7.
. 2011. “A West Nile Virus Dna Vaccine Utilizing A Modified Promoter Induces Neutralizing Antibody In Younger And Older Healthy Adults In A Phase I Clinical Trial.”. J Infect Dis 203 (10). J Infect Dis: 1396-404. doi:10.1093/infdis/jir054.
. 2011. “A Sars Dna Vaccine Induces Neutralizing Antibody And Cellular Immune Responses In Healthy Adults In A Phase I Clinical Trial.”. Vaccine 26 (50). Vaccine: 6338-43. doi:10.1016/j.vaccine.2008.09.026.
. 2008. “Safety, Immunogenicity And Efficacy Of Modified Vaccinia Ankara (Mva) Against Dryvax Challenge In Vaccinia-Naïve And Vaccinia-Immune Individuals.”. Vaccine 25 (8). Vaccine: 1513-25. doi:10.1016/j.vaccine.2006.10.047.
. 2007.